Reuters Health Report

Click to View in Browser 04/30/2014 Drug resistant superbugs a serious threat worldwide, says WHO LONDON, April 30 (Reuters) - The spread of deadly superbugs that evade even the most powerful antibiotics is no longer a prediction but is happening right now across the world, United Nations officials said on Wednesday. Incorrect biopsy results cloud Nymox Pharma prostate cancer study (Reuters) - Nymox Pharmaceutical Corp said its experimental prostate cancer drug reduced the progression of cancer in patients, but it could not determine if the study succeeded in meeting pre-determined goals due to a high rate of incorrect biopsies. J&J suspends sale of device used in fibroid surgery (Reuters) - Johnson & Johnson suspended worldwide sale of its device used in fibroid surgery amid concerns over its potential to spread undetected cancer beyond the uterus. Genetic yacht lab maps sea life off Florida looking for cures ORLANDO Fla. (Reuters) - A team of scientists has begun collecting the genomes of sea creatures off the Florida coast in the hopes that unmapped species, some of which have the capacity to reverse disease and injury in themselves, may hold the key to new treatments for humans. GE eases ahead in race for Alstom power assets PARIS (Reuters) - Cash-strapped French engineering group Alstom said on Wednesday it would explore a $16.9 billion offer from General Electric for its energy arm while leaving the door open to a rival bid from Germany's Siemens. GSK says staying on sidelines in Astra, Pfizer fight LONDON (Reuters) - GlaxoSmithKline is just an "interested observer" as U.S. drugmaker Pfizer battles to win British rival AstraZeneca in a potential $100 billion deal, GSK's chief executive said on Wednesday. China approves Merck KGaA's takeover of AZ Electronic BEIJING (Reuters) - China's commerce ministry has approved with conditions German liquid crystal maker Merck KGaA's planned $2.6 billion takeover of UK-listed AZ Electronic Materials . India court orders temporary halt on Sun Pharma's $3.2 billion takeover of Ranbaxy MUMBAI (Reuters) - An Indian court has temporarily halted generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion takeover of rival Ranbaxy Laboratories Ltd until it decides on a petition for a probe into alleged insider trading. Related Video Rotting, bloated Blue whale worries Canadian fishing community Elephant dung recycled into 'poo paper' The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend